title: Oxidative stress parameters in urine from patients with disorders of propionate metabolism: a beneficial effect of L:-carnitine supplementation.
abstract: Propionic (PA) and methylmalonic (MMA) acidurias are inherited disorders caused by deficiency of propionyl-CoA carboxylase and methylmalonyl-CoA mutase, respectively. Affected patients present acute metabolic crises in the neonatal period and long-term neurological deficits. Treatments of these diseases include a protein restricted diet and L: -carnitine supplementation. L: -Carnitine is widely used in the therapy of these diseases to prevent secondary L: -carnitine deficiency and promote detoxification, and several recent in vitro and in vivo studies have reported antioxidant and antiperoxidative effects of this compound. In this study, we evaluated the oxidative stress parameters, isoprostane and di-tyrosine levels, and the antioxidant capacity, in urine from patients with PA and MMA at the diagnosis, and during treatment with L: -carnitine and protein-restricted diet. We verified a significant increase of isoprostanes and di-tyrosine, as well as a significant reduction of the antioxidant capacity in urine from these patients at diagnosis, as compared to controls. Furthermore, treated patients presented a marked reduction of isoprostanes and di-tyrosine levels in relation to untreated patients. In addition, patients with higher levels of protein and lipid oxidative damage, determined by di-tyrosine and isoprostanes levels, also presented lower urinary concentrations of total and free L: -carnitine. In conclusion, the present results indicate that treatment with low protein diet and L: -carnitine significantly reduces urinary biomarkers of protein and lipid oxidative damage in patients with disorders of propionate metabolism and that L: -carnitine supplementation may be specially involved in this protection.
authors.affiliation: Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Ipiranga 2752, Porto Alegre, RS, 90610-000, Brazil. grazischmitt@terra.com.br
authors.forename: Graziela S
authors.initials: GS
authors.lastname: Ribas
authors.forename: Giovana B
authors.initials: GB
authors.lastname: Biancini
authors.forename: Caroline
authors.initials: C
authors.lastname: Mescka
authors.forename: Carlos Y
authors.initials: CY
authors.lastname: Wayhs
authors.forename: Angela
authors.initials: A
authors.lastname: Sitta
authors.forename: Moacir
authors.initials: M
authors.lastname: Wajner
authors.forename: Carmen R
authors.initials: CR
authors.lastname: Vargas
mesh_terms: D000592:Amino Acid Metabolism, Inborn Errors / Q000178:diet therapy* / Q000378:metabolism / Q000652:urine*; D000975:Antioxidants / Q000032:analysis / Q000378:metabolism; D002331:Carnitine / Q000008:administration & dosage / Q000032:analysis / Q000627:therapeutic use* / Q000652:urine; D002648:Child; D002675:Child, Preschool; D018753:Diet, Protein-Restricted; D019587:Dietary Supplements; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016555:Matched-Pair Analysis; D008764:Methylmalonic Acid / Q000378:metabolism / Q000652:urine; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D011422:Propionates / Q000378:metabolism* / Q000652:urine; D016896:Treatment Outcome; D014443:Tyrosine / Q000032:analysis / Q000652:urine
chemical_list: D000975:Antioxidants; D011422:Propionates; D014443:Tyrosine; D008764:Methylmalonic Acid; D002331:Carnitine